Perhaps one reason PFE initially sold off so sharply today is the ghost of Torcetrapib—i.e. the irrational fear that PFE’s most consequential drug candidate is doomed just because it belongs to PFE.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”